174 related articles for article (PubMed ID: 36434570)
1. Diagnostic performance of an immunoassay based on urine exfoliated cell enrichment nanotechnology for upper tract urothelial carcinoma: a retrospective, monocentric study.
Wang X; Zhang S; Wu L; Feng B; Shen H; Gu Y; Zhang Q; Fang F; Yang R; Guo H
BMC Urol; 2022 Nov; 22(1):194. PubMed ID: 36434570
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
[TBL] [Abstract][Full Text] [Related]
3. Unbiased enrichment of urine exfoliated cells on nanostructured substrates for sensitive detection of urothelial tumor cells.
Wang X; Gu Y; Zhang S; Li G; Liu T; Wang T; Qin H; Jiang B; Zhu L; Li Y; Lei H; Li M; Zhang Q; Yang R; Fang F; Guo H
Cancer Med; 2020 Jan; 9(1):290-301. PubMed ID: 31709750
[TBL] [Abstract][Full Text] [Related]
4. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.
Messer J; Shariat SF; Brien JC; Herman MP; Ng CK; Scherr DS; Scoll B; Uzzo RG; Wille M; Eggener SE; Steinberg G; Terrell JD; Lucas SM; Lotan Y; Boorjian SA; Raman JD
BJU Int; 2011 Sep; 108(5):701-5. PubMed ID: 21320275
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma.
Su X; Hao H; Li X; He Z; Gong K; Zhang C; Cai L; Zhang Q; Yao L; Ding Y; Gong Y; Fang D; Zhang Z; Zhou L
Oncotarget; 2017 Apr; 8(16):26106-26111. PubMed ID: 28212539
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study.
Freund JE; Liem EIML; Savci-Heijink CD; de Reijke TM
Med Oncol; 2018 Nov; 36(1):10. PubMed ID: 30499061
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens.
Yu Q; Li Y; Li G; Li T; Zeng H; Yang Z; Wang D
Oncol Lett; 2016 Jul; 12(1):183-188. PubMed ID: 27347122
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
10. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][
